A National Bowel Cancer Screening Programme using FIT: Achievements and Challenges.


Journal

Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 05 2018
revised: 25 09 2018
accepted: 28 11 2018
pubmed: 6 12 2018
medline: 15 4 2020
entrez: 6 12 2018
Statut: ppublish

Résumé

Colorectal cancer accounts for 11% of all cancer-related deaths in Ireland. With the aim of diagnosing these cancers at an earlier stage, and detecting premalignant lesions, the National Screening Service (NSS) offered a fecal immunochemical test (FIT) to all individuals aged 60 to 69. All individuals in the age range were contacted by post and invited to participate in the programme. Those with a positive FIT result were offered a colonoscopy in an internationally accredited unit. From an eligible population of 488,628, 196,238 individuals participated giving an uptake of 40.2%. Commencing at a FIT threshold of 20 μg Hg/g feces, the positivity rate was 8.6%, which overwhelmed colonoscopy capacity and, thus, the threshold was increased to 45 μg, resulting in an overall 5% positivity rate. A total of 520 individuals had cancer detected (68.3% stage I or II), of which 104 were removed endoscopically (pT1s). Adenomas were present in 54.2% of all colonoscopies, 17.4% deemed high risk. Despite a lower uptake, males were twice as likely to have colorectal cancers as females and had a 59% increased rate of high-risk adenomas diagnosed. Challenges facing the programme include increasing participation, especially among males, and increasing colonoscopy capacity. The ability to alter the sensitivity of FIT to match colonoscopy capacity is a valuable option for such a programme as it ensures that the maximum public health benefit can be achieved within available resources.

Identifiants

pubmed: 30514807
pii: 1940-6207.CAPR-18-0182
doi: 10.1158/1940-6207.CAPR-18-0182
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-94

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Diarmuid O'Donoghue (D)

BowelScreen, The National Screening Service, Dublin, Ireland. bowelscreen.q&a@screeningservice.ie.

Kieran Sheahan (K)

Clinical Advisory Group. The National Screening Service, Dublin, Ireland.

Padraic MacMathuna (P)

Clinical Advisory Group. The National Screening Service, Dublin, Ireland.

Richard B Stephens (RB)

Clinical Advisory Group. The National Screening Service, Dublin, Ireland.

Helen Fenlon (H)

Clinical Advisory Group. The National Screening Service, Dublin, Ireland.

Martina Morrin (M)

Clinical Advisory Group. The National Screening Service, Dublin, Ireland.

Jenny Mooney (J)

BowelScreen, The National Screening Service, Dublin, Ireland.

Lorraine E Fahy (LE)

BowelScreen, The National Screening Service, Dublin, Ireland.

Therese Mooney (T)

BowelScreen, The National Screening Service, Dublin, Ireland.

Alan Smith (A)

BowelScreen, The National Screening Service, Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH